Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC

To study induction therapy with Nab-paclitaxel, Cisplatin and Pembrolizumab in patients with Locally Advanced HNSCC.

Trial Details

NCT ID
NCT05272696
Phase
PHASE2
Sponsor
Guangdong Provincial People's Hospital
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • Nab-paclitaxel, cisplatin and Pembrolizumab combination
  • surgery
  • Adjuvant Chemoradiotherapy
  • Radical concurrent chemoradiotherapy
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Histologically or cytologically confirmed Head and Neck Squamous Cell Carcinoma (oral cavity, oropharynx, laryngeal and hypopharynx) with locoregio…
  • Measurable disease based on RECIST 1.1
  • ECOG performance status 0-1
  • Men and women, Age ≥18 and ≤ 70 years at the time of signing informed consent,

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →